Evaluating the effectiveness of a pharmacist-led IT-based intervention when widely implemented

Evaluating the effectiveness, and cost-effectiveness, of a pharmacist-led IT-based intervention (PINCER) when widely implemented in general practices to reduce the prevalence of patient exposure to hazardous prescribing, and the incidence of serious harm

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

ISRCTN

Registry ID

ISRCTN12035620

Enrollment

350

Registered

2021-03-11

Start date

2020-09-08

Completion date

Unknown

Last updated

2023-04-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hazardous prescribing Not Applicable

Interventions

This is a multi-centre, primary care observational study utilising routinely recorded primary care data linked to other national datasets. Up to 350 general practices known to the stud

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Inclusion criteria for general practices: 1. Agree to take part and sign the organisation information document 2. Practices within the East Midlands who have taken part in the Health Foundation Scaling Up PINCER project Inclusion criteria for patients: 1. All patients in the general practices taking part in the study

Exclusion criteria

Exclusion criteria: Exclusion criteria for general practices: 1. Practices who have not taken part in the Health Foundation Scaling Up PINCER project Exclusion criteria for patients: 2. Patients with a computer code in their clinical records indicating that they do not wish for their medical records to be used for research or secondary purposes

Design outcomes

Primary

Measure	Time frame
The number and proportion of patients in each general practice exposed to at least one type of hazardous prescribing; the deidentified data for all outcome measures will be extracted from routinely recorded primary care data for a maximum of 27 audit dates over a 78-month period (28/02/2013 to 31/08/2019) and analysed quarterly.	—

Secondary

Measure	Time frame
The number and proportion of patients within each general practice: 1. With 11 specific types of hazardous prescribing 2. With serious harm (composite measure), and the following types of serious harm (associated with particular types of hazardous prescribing): 2.1. Gastrointestinal bleeding 2.2. Exacerbation of asthma 2.3. Heart failure 2.4. Stroke 2.5. Acute kidney injury 3. With a hospital admission 4. With death 5. Exposed to specific types of hazardous prescribing The deidentified data for all outcome measures will be extracted from routinely recorded primary care data extracted for a maximum of 27 audit dates over a 78-month period (28/02/2013 to 31/08/2019) and analysed quarterly.	—

Measure

Time frame

The number and proportion of patients within each general practice: 1. With 11 specific types of hazardous prescribing 2. With serious harm (composite measure), and the following types of serious harm (associated with particular types of hazardous prescribing): 2.1. Gastrointestinal bleeding 2.2. Exacerbation of asthma 2.3. Heart failure 2.4. Stroke 2.5. Acute kidney injury 3. With a hospital admission 4. With death 5. Exposed to specific types of hazardous prescribing The deidentified data for all outcome measures will be extracted from routinely recorded primary care data extracted for a maximum of 27 audit dates over a 78-month period (28/02/2013 to 31/08/2019) and analysed quarterly.

—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026